Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101906 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01101906 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 23 participants.
The verdict
NCT01101906, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
Interventions
- DRUG Placebo
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-01-10 |
| Est. Completion | 2011-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101906
The ClinicalTrials.gov registry entry for NCT01101906 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01101906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101906 about?
NCT01101906 is a clinical study titled "A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC". This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
What is the current status of trial NCT01101906?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-01-10. Estimated completion is 2011-12-28.
What interventions are being tested in trial NCT01101906?
The interventions under investigation include: Placebo (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01101906?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.